Major pharmaceutical companies announce multibillion-dollar investments in the US

Major multinational pharmaceutical firms, including Pfizer, AstraZeneca, Eli Lilly, and GSK, have pledged approximately $500 billion to expand their operations, research, and infrastructure within the United States. This move is part of a broader strategy to strengthen their domestic presence and supply chains, driven by specific agreements and policy shifts under the administration of U.S. President Donald Trump.

On September 30, Pfizer reached an agreement with President Trump to invest $70 billion in research, development, and domestic production. In exchange, the company secured a three-year grace period exempting its products from current pharmaceutical tariffs. Additionally, GSK plans to invest $30 billion in research and supply chain infrastructure over the next five years. Furthermore, President Trump announced in January that Eli Lilly is set to construct six factories in the U.S., an expansion from the company's previous commitment last year to spend at least $27 billion on four facilities.

These commitments reflect a significant shift in corporate planning aimed at localizing production and enhancing R&D capabilities. While these investments are framed as a response to evolving economic conditions and trade policies, the companies remain focused on long-term infrastructure development as they navigate the current regulatory and tariff landscape in the American market.